BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31662784)

  • 1. Analysis of a Multiple Delays Model for Treatment of Cancer with Oncolytic Virotherapy.
    El Alami Laaroussi A; Hia ME; Rachik M; Ghazzali R
    Comput Math Methods Med; 2019; 2019():1732815. PubMed ID: 31662784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial Model for Oncolytic Virotherapy with Lytic Cycle Delay.
    Zhao J; Tian JP
    Bull Math Biol; 2019 Jul; 81(7):2396-2427. PubMed ID: 31089864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mathematical model of oncolytic virotherapy with time delay.
    Wang ZZ; Guo ZM; Smith H
    Math Biosci Eng; 2019 Mar; 16(4):1836-1860. PubMed ID: 31137188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The replicability of oncolytic virus: defining conditions in tumor virotherapy.
    Tian JP
    Math Biosci Eng; 2011 Jul; 8(3):841-60. PubMed ID: 21675814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mathematical approach to effects of CTLs on cancer virotherapy in the second injection of virus.
    Ashyani A; RabieiMotlagh O; Mohammadinejad HM
    J Theor Biol; 2018 Sep; 453():78-87. PubMed ID: 29782928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Backward Hopf bifurcation in a mathematical model for oncolytic virotherapy with the infection delay and innate immune effects.
    Guo Y; Niu B; Tian JP
    J Biol Dyn; 2019 Dec; 13(1):733-748. PubMed ID: 31532345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mathematical model for cell cycle-specific cancer virotherapy.
    Crivelli JJ; Földes J; Kim PS; Wares JR
    J Biol Dyn; 2012; 6 Suppl 1():104-20. PubMed ID: 22873678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach.
    Mahasa KJ; Eladdadi A; de Pillis L; Ouifki R
    PLoS One; 2017; 12(9):e0184347. PubMed ID: 28934210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Questing for an optimal, universal viral agent for oncolytic virotherapy.
    Paiva LR; Martins ML; Ferreira SC
    Phys Rev E Stat Nonlin Soft Matter Phys; 2011 Oct; 84(4 Pt 1):041918. PubMed ID: 22181186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New perspectives in cancer virotherapy: bringing the immune system into play.
    Boisgerault N; Tangy F; Gregoire M
    Immunotherapy; 2010 Mar; 2(2):185-99. PubMed ID: 20635927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic viruses in cancer therapy.
    Vähä-Koskela MJ; Heikkilä JE; Hinkkanen AE
    Cancer Lett; 2007 Sep; 254(2):178-216. PubMed ID: 17383089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oscillations in a Spatial Oncolytic Virus Model.
    Baabdulla AA; Hillen T
    Bull Math Biol; 2024 Jun; 86(8):93. PubMed ID: 38896363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis.
    Malinzi J; Ouifki R; Eladdadi A; Torres DFM; White JKA
    Math Biosci Eng; 2018 Dec; 15(6):1435-1463. PubMed ID: 30418793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the Spatiotemporal Dynamics of Oncolytic Viruses and Radiotherapy as a Treatment for Cancer.
    Simbawa E; Al-Johani N; Al-Tuwairqi S
    Comput Math Methods Med; 2020; 2020():3642654. PubMed ID: 32411281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling of cancer virotherapy with recombinant measles viruses.
    Bajzer Z; Carr T; Josić K; Russell SJ; Dingli D
    J Theor Biol; 2008 May; 252(1):109-22. PubMed ID: 18316099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex spatial dynamics of oncolytic viruses in vitro: mathematical and experimental approaches.
    Wodarz D; Hofacre A; Lau JW; Sun Z; Fan H; Komarova NL
    PLoS Comput Biol; 2012; 8(6):e1002547. PubMed ID: 22719239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational modeling approaches to studying the dynamics of oncolytic viruses.
    Wodarz D
    Math Biosci Eng; 2013 Jun; 10(3):939-57. PubMed ID: 23906157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Virotherapy by HSV.
    Watanabe D; Goshima F
    Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico evolutionary dynamics of tumour virotherapy.
    Reis CL; Pacheco JM; Ennis MK; Dingli D
    Integr Biol (Camb); 2010 Jan; 2(1):41-5. PubMed ID: 20473411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic analysis of an age structure model for oncolytic virus therapy.
    Gao L; Tan Y; Yang J; Xiang C
    Math Biosci Eng; 2023 Jan; 20(2):3301-3323. PubMed ID: 36899582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.